急性髓样白血病（AML）是影响成年人最常见和致命的一种白血病。 它通常通过多轮非特异性化疗和造血干细胞移植进行管理，但仅有那些能够耐受这种严酷治疗的患者才可能接受该治疗，而很多患者都是老年和虚弱的。 随着新型肿瘤特异性细胞表面受体的发现，人们极为确信靶向抗体治疗将很快成为这些患者的一种选择。 在本综述中，我们描述了已知的单特异性和双特异性抗体治疗AML的靶点受体的当前局面。 在这里，我们对正在开发的每种受体和靶向抗体治疗进行了表征，阐明了每种治疗化合物的合理设计。 然后，我们讨论了正在研发的双特异性抗体以及它们如何改善AML的免疫监视。 对于每种治疗，我们还总结了可获得的临床前和临床数据，包括来自终止试验的数据。 其中一种基于抗体的治疗已经获得了AML治疗的批准，即针对CD33的抗体药物结合物gemtuzumab ozogamicin。 目前还有更多这样的抗体治疗正在进行临床前和临床研究。这些基于抗体的治疗可以执行特异性肿瘤，复杂的细胞毒性功能，人们越来越有信心它们将很快导致个性化，安全的AML治疗选择，诱导持久的缓解。

Acute myeloid leukemia (AML) is the most common and deadly type of leukemia affecting adults. It is typically managed with rounds of non-targeted chemotherapy followed by hematopoietic stem cell transplants, but this is only possible in patients who can tolerate these harsh treatments and many are elderly and frail. With the identification of novel tumor-specific cell surface receptors, there is great conviction that targeted antibody therapies will soon become available for these patients.In this review, we describe the current landscape of known target receptors for monospecific and bispecific antibody-based therapeutics for AML. Here, we characterize each of the receptors and targeted antibody-based therapeutics in development, illustrating the rational design behind each therapeutic compound. We then discuss the bispecific antibodies in development and how they improve immune surveillance of AML. For each therapeutic, we also summarize the available pre-clinical and clinical data, including data from discontinued trials.One antibody-based therapeutic has already been approved for AML treatment, the CD33-targeting antibody-drug conjugate, gemtuzumab ozogamicin. Many more are currently in pre-clinical and clinical studies. These antibody-based therapeutics can perform tumor-specific, elaborate cytotoxic functions and there is growing confidence they will soon lead to personalized, safe AML treatment options that induce durable remissions.